EP Patent

EP4385980A1 — Indazoles as inhibitors of nav1.8

Assigned to Gruenenthal GmbH · Expires 2024-06-19 · 2y expired

What this patent protects

The invention relates to compounds according to general formula (I)which act as inhibitors of Navl.8 and can be used in the treatment of pain.

USPTO Abstract

The invention relates to compounds according to general formula (I)which act as inhibitors of Navl.8 and can be used in the treatment of pain.

Drugs covered by this patent

Journavx (SUZETRIGINE) · Vertex Pharms Inc

Patent Metadata

Patent number: EP4385980A1
Jurisdiction: EP
Classification: —
Expires: 2024-06-19
Drug substance claim: No
Drug product claim: No
Assignee: Gruenenthal GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.